Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 14, 2013 - Issue 17
Submit an article Journal homepage
720
Views
22
CrossRef citations to date
0
Altmetric
Editorial

Psoriatic arthritis: advances in pharmacotherapy based on molecular target

Raffaele ScarpaUniversity Federico II, Rheumatology Research Unit, Department of Clinical and Experimental Medicine, via S. Pansini 5, 80131 – Naples, Italy+39 081 7462063; +39 081 5463445; [email protected]
, MD,
Luisa CostaUniversity Federico II, Rheumatology Research Unit, Department of Clinical and Experimental Medicine, via S. Pansini 5, 80131 – Naples, Italy+39 081 7462063; +39 081 5463445; [email protected]
, MD,
Mariangela AttenoUniversity Federico II, Rheumatology Research Unit, Department of Clinical and Experimental Medicine, via S. Pansini 5, 80131 – Naples, Italy+39 081 7462063; +39 081 5463445; [email protected]
, MD,
Antonio Del PuenteUniversity Federico II, Rheumatology Research Unit, Department of Clinical and Experimental Medicine, via S. Pansini 5, 80131 – Naples, Italy+39 081 7462063; +39 081 5463445; [email protected]
, MD,
Francesco CasoUniversity of Padova, Rheumatology Unit, Department of Medicine DIMED, Padova, Italy
, MD PhD St &
John MH MollEmeritus Consultant Rheumatologist, Sheffield, UK
, DM PhD FRCP
Pages 2311-2313 | Published online: 25 Sep 2013

Figures & data

This paper does not have figures.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
Source: Wiley
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Source: Wiley
New treatment targets in ankylosing spondylitis and other spondyloarthritides.
Source: Ovid Technologies (Wolters Kluwer Health)
Emerging drugs for psoriatic arthritis
Source: Informa Healthcare
Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study
Source: The Journal of Rheumatology
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.
Source: Springer Science and Business Media LLC
Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Source: Hindawi Limited
Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management
Source: Springer Science and Business Media LLC
Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
Source: The Journal of Rheumatology
When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.
Source: Wiley
Psoriatic arthritis: current therapy and future directions.
Source: Informa Healthcare

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.